GlaxoSmithKline Seeks Closure in $235M Patent Case, Urges Court to Reject Teva’s Retrial Request

In a protracted legal battle spanning over a decade, GlaxoSmithKline (GSK) has urged a Delaware federal judge to dismiss Teva Pharmaceuticals’ latest request for a retrial. The dispute centers around a $235 million “skinny label” patent conflict concerning heart failure medication. According to GSK, Teva’s appeal represents an “eighth bite at the same apple,” suggesting that Teva has repeatedly sought retrials in this extensive litigation process. For further details, visit the full article on Law360.